Kwang Dong’s targeted therapy Afinitor challenges to patent
Kwang Dong Pharmaceutical started to develop a first generic of ‘Afinitor(generic name: everolimus),’ a Novartis’ targeted therapy.
Used to treat diseases such as breast cancer and renal cancer, Afinitor is recording annually KRW 15 billion sales.
On the 28th, the Ministry of Food and Drug Safe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
